Market news

Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.

Earlier in September 2026, Revolution Medicines announced that the FDA granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib) plus chemotherapy for treatment‑naïve metastatic pancreatic adenocarcinoma, adding to its existing U.S. approval in later‑line PDAC. The company was also added to the FTSE All‑World Index (USD), potentially broadening its shareholder base as it advances a late‑stage RAS(ON) pipeline in a cancer with very limited treatment options. With Breakthrough...

Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancerSurvival data highlighted in accompanying...

Revolution Medicines (NasdaqGS: RVMD) received FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib) in metastatic pancreatic adenocarcinoma. The designation covers RASONQUE in combination with existing chemotherapy for patients who have not previously received treatment. Breakthrough Therapy status may provide access to expedited FDA interactions and review processes for this treatment candidate. The Breakthrough Therapy Designation for RASONQUE in first line metastatic...

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 33.5% on an annualized basis producing an average annual return of 45.32%. Currently, Revolution Medicines has a market

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]

Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for patients with RAS-addicted cancers REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cance

Reuters reported that the FDA approved Revolution Medicines, Inc. (NASDAQ:RVMD) Rasonque (daraxonrasib) on August 26 for adults with metastatic pancreatic cancer who have already received prior treatment or cannot receive combination chemotherapy. The once-daily pill is the first broad RAS-targeted medicine approved for pancreatic cancer, designed to block several forms of the RAS protein that […]

--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a drug concentration that can be achieved with current sabizabulin human dosing with good safety-- --Oral sabizabulin had a good safety profile and promising efficacy in previous first-in-man Phase 1b/2 clinical study of 80 subjects with castration resistant and taxane resistant met

Revolution Medicines (NasdaqGS:RVMD) reported US FDA approval of RASONQUE for adults with previously treated metastatic pancreatic adenocarcinoma, the first broad RAS targeted therapy for this cancer type. RASONQUE is the first approved therapy from a new class of RAS(ON) multi selective inhibitors aimed at tumors driven by RAS mutations. Phase 1/2 clinical data for RASONQUE in RAS mutant non small cell lung cancer were published in the New England Journal of Medicine, providing independent...

Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review. The once-daily oral RAS inhibitor is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Revolution Medicines, Inc. (NASDAQ:RVMD) set a wholesale acquisition cost (WAC) […]

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from th

Revolution Medicines holds $3.9B in cash, supported by recent financings and a $2B Royalty Pharma agreement. Read why RVMD stock is a Strong Buy.

Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor targeting metastatic pancreatic cancer.

Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP. RBC noted that while prior data was too limited for firm conclusions, the update should look “very competitive” and support ongoing Phase 3 efforts in first-line pancreatic ductal […]

Revolution Medicines, Inc. (NASDAQ:RVMD) touched an all-time high above $224 on August 27, 2026, following FDA approval of Rasonque (daraxonrasib) – the first broad RAS-targeted therapy cleared for metastatic pancreatic cancer. Creating a milestone, the approval came roughly five weeks after filing under the agency’s national priority voucher. The pivotal RASolute 302 trial nearly doubled […]

Revolution Medicines (NASDAQ:RVMD) said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma. The oral, once-daily RAS(ON) multi-selective inhibitor is approved for adults with metastatic pancreati

Detailed price information for Amgen Inc (AMGN-Q) from The Globe and Mail including charting and trades.

The FDA has approved a new pill for one of the most common forms of pancreatic cancer. What to know about managing the financial impact of a cancer diagnosis.

Detailed price information for Agilent Technologies (A-N) from The Globe and Mail including charting and trades.

Revolution Medicines (RVMD) is in focus after the U.S. Food and Drug Administration approved RASONQUE, a once daily oral RAS inhibitor for certain adults with metastatic pancreatic adenocarcinoma following prior treatment. Revolution Medicines' share price has reacted strongly around these developments, with a 1-month share price return of 22.24% and a 3-month share price return of 40.43% helping lift the stock to US$221.15. The 1-year total shareholder return is also very large, indicating...

Earlier this week, Revolution Medicines announced that the FDA approved RASONQUE (daraxonrasib), a once-daily oral treatment for previously treated or fragile adults with metastatic pancreatic adenocarcinoma, marking the first broadly RAS-targeted therapy in this hard-to-treat cancer. The approval was backed by the Phase 3 RASolute 302 trial, where RASONQUE cut the risk of death versus chemotherapy while maintaining a more manageable safety profile and quality of life, without requiring a...

Revolution Medicines (NasdaqGS:RVMD) received FDA approval for RASONQUE (daraxonrasib) as the first broad RAS-targeted treatment for metastatic pancreatic cancer. The approval introduces a new class of RAS-targeted therapies for a cancer type with historically limited treatment options and poor outcomes. Clinical trials for RASONQUE reported survival benefits and quality of life improvements compared with standard chemotherapy. The decision marks a milestone for Revolution Medicines in...

CEO Mark Goldsmith said discussions with insurers gave the company confidence that they understand the drug’s clinical value.